Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee

BACKGROUND: The phase 2 PACE (Ponatinib Ph+ ALL and CML Evaluation) trial of ponatinib showed robust long-term benefit in relapsed Philadelphia chromosome-positive (Ph+) leukemia; arterial occlusive events (AOEs) occurred in ≥ 25% of patients based on investigator reporting. However, AOE rates vary...

Descripción completa

Detalles Bibliográficos
Autores principales: Januzzi, James L., Garasic, Joseph M., Kasner, Scott E., McDonald, Vickie, Petrie, Mark C., Seltzer, Jonathan, Mauro, Michael, Croce, Kevin, Berman, Ellin, Deininger, Michael, Hochhaus, Andreas, Pinilla-Ibarz, Javier, Nicolini, Franck, Kim, Dong-Wook, DeAngelo, Daniel J., Kantarjian, Hagop, Xu, Jing, Hall, Tracey, Srivastava, Shouryadeep, Naranjo, Daniel, Cortes, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734305/
https://www.ncbi.nlm.nih.gov/pubmed/34991679
http://dx.doi.org/10.1186/s13045-021-01221-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734305/
https://www.ncbi.nlm.nih.gov/pubmed/34991679
http://dx.doi.org/10.1186/s13045-021-01221-z

Ejemplares similares